Ken Griffin Enanta Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 5,600 shares of ENTA stock, worth $40,208. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,600

Previous 9,700 42.27%

Holding current value

$40,208

Previous $55,000 45.45%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$4.82 - $8.49 $449,860 - $792,388	-93,332 Reduced 58.97%	64,926 $358,000
Q4 2024 Feb 14, 2025	SELL	$5.75 - $12.99 $2.96 Million - $6.68 Million	-514,622 Reduced 76.48%	158,258 $909,000
Q3 2024 Nov 14, 2024	BUY	$10.05 - $16.54 $2.09 Million - $3.43 Million	207,505 Added 44.59%	672,880 $6.98 Million
Q2 2024 Aug 14, 2024	BUY	$11.43 - $17.02 $4.68 Million - $6.98 Million	409,812 Added 737.56%	465,375 $6.04 Million
Q1 2024 May 15, 2024	SELL	$10.08 - $17.46 $109,700 - $190,017	-10,883 Reduced 16.38%	55,563 $970,000
Q4 2023 Feb 14, 2024	SELL	$8.18 - $10.78 $1.06 Million - $1.4 Million	-129,795 Reduced 66.14%	66,446 $625,000
Q3 2023 Nov 14, 2023	SELL	$11.09 - $22.13 $177,184 - $353,571	-15,977 Reduced 7.53%	196,241 $2.19 Million
Q2 2023 Aug 14, 2023	SELL	$20.68 - $39.85 $1.63 Million - $3.14 Million	-78,739 Reduced 27.06%	212,218 $4.54 Million
Q1 2023 May 15, 2023	BUY	$38.82 - $54.59 $7.02 Million - $9.87 Million	180,891 Added 164.35%	290,957 $11.8 Million
Q4 2022 Feb 14, 2023	BUY	$40.77 - $53.73 $3.1 Million - $4.09 Million	76,104 Added 224.09%	110,066 $5.12 Million
Q3 2022 Nov 14, 2022	BUY	$48.29 - $71.27 $1.64 Million - $2.42 Million	33,962 New	33,962 $1.76 Million
Q1 2022 May 16, 2022	BUY	$56.06 - $74.11 $379,582 - $501,798	6,771 Added 29.18%	29,972 $2.13 Million
Q4 2021 Feb 14, 2022	SELL	$60.19 - $97.37 $1.58 Million - $2.56 Million	-26,293 Reduced 53.12%	23,201 $1.73 Million
Q3 2021 Nov 15, 2021	SELL	$41.02 - $58.65 $1.65 Million - $2.36 Million	-40,253 Reduced 44.85%	49,494 $2.81 Million
Q2 2021 Aug 16, 2021	SELL	$43.76 - $53.11 $393,489 - $477,565	-8,992 Reduced 9.11%	89,747 $3.95 Million
Q1 2021 May 17, 2021	BUY	$41.69 - $54.95 $450,668 - $594,009	10,810 Added 12.29%	98,739 $4.87 Million
Q4 2020 Feb 16, 2021	BUY	$41.16 - $47.47 $1.45 Million - $1.67 Million	35,140 Added 66.57%	87,929 $3.7 Million
Q3 2020 Nov 16, 2020	BUY	$43.36 - $53.53 $429,437 - $530,161	9,904 Added 23.09%	52,789 $2.42 Million
Q2 2020 Aug 14, 2020	SELL	$46.37 - $57.58 $4.16 Million - $5.16 Million	-89,608 Reduced 67.63%	42,885 $2.15 Million
Q1 2020 May 15, 2020	BUY	$40.22 - $62.0 $3 Million - $4.62 Million	74,579 Added 128.78%	132,493 $6.81 Million
Q4 2019 Feb 14, 2020	SELL	$57.95 - $66.61 $1.9 Million - $2.18 Million	-32,749 Reduced 36.12%	57,914 $3.58 Million
Q3 2019 Nov 14, 2019	SELL	$60.08 - $88.17 $10.5 Million - $15.5 Million	-175,444 Reduced 65.93%	90,663 $5.45 Million
Q2 2019 Aug 14, 2019	BUY	$81.3 - $97.35 $1.33 Million - $1.59 Million	16,335 Added 6.54%	266,107 $22.5 Million
Q1 2019 May 15, 2019	BUY	$69.08 - $105.66 $16.5 Million - $25.3 Million	239,141 Added 2249.47%	249,772 $0
Q4 2018 Feb 14, 2019	BUY	$65.41 - $84.65 $177,522 - $229,740	2,714 Added 34.28%	10,631 $752,000
Q3 2018 Nov 13, 2018	SELL	$85.46 - $126.37 $963,305 - $1.42 Million	-11,272 Reduced 58.74%	7,917 $0
Q2 2018 Aug 10, 2018	BUY	$81.85 - $120.51 $97,810 - $144,009	1,195 Added 6.64%	19,189 $0
Q1 2018 May 11, 2018	BUY	$57.91 - $92.15 $676,620 - $1.08 Million	11,684 Added 185.17%	17,994 $1.46 Million
Q3 2017 Nov 09, 2017	BUY	$37.91 - $46.8 $239,212 - $295,308	6,310	6,310 $295,000

Others Institutions Holding ENTA

# of Institutions

112

Shares Held

18.8M

Call Options Held

5.6K

Put Options Held

13.9K

View Full List

About ENANTA PHARMACEUTICALS INC

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $149M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

More about ENTA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account